Pharma's biggest name dominated Monday's session as reports of AstraZeneca-Bristol Myers merger talks wiped billions off the Cambridge drugmaker's valuation, overshadowing a run of smaller diagnostics and biotech updates. Elsewhere, the day's news flow skewed toward clinical validation and commercial traction: Edx Medical's pneumonia test went live in an NHS intensive care unit, BSF Enterprise struck a US leather joint venture, and Cizzle Biotechnology's American partner signed up a second laboratory. Genedrive, CelLBxHealth, Coiled Therapeutics and Genflow Biosciences all advanced narrower but material clinical and patent milestones.
AstraZeneca slides on reports of Bristol Myers merger talks
AstraZeneca (LSE:AZN) dropped sharply on Monday after reports emerged that Britain's biggest drugmaker had explored a merger with US rival Bristol Myers Squibb. A combined entity would be worth close to $400 billion, creating the industry's fourth-largest company by market value. AstraZeneca entered the session with a market capitalisation of roughly $264 billion against Bristol Myers' $133 billion, and the Cambridge-headquartered group's shares fell close to 9%, dropping 1,112p to change hands at 11,436p and dragging on the wider FTSE 100.
Sources cautioned the talks, which have taken place in recent months, may never produce a deal, and neither company has confirmed discussions. Bristol Myers shares rose 6% in premarket trading in a mirror reaction. The two firms have history: they partnered on diabetes therapies in 2007, before AstraZeneca bought out its partner's stake in that alliance in 2013 for $2.7 billion upfront. Bristol Myers, best known for its cancer treatments, faces looming loss of exclusivity on several drugs even as its shares have performed strongly over the past year on better-than-expected earnings.
Analysts questioned the logic given AstraZeneca's own momentum. Chief executive Pascal Soriot has rebuilt the company's pipeline roughly cancer immunotherapies since fending off a hostile £70 billion approach from Pfizer in 2014, and AstraZeneca is targeting $80 billion in sales by 2030, up from $58.7 billion last year. The group has also already committed $50 billion to US research and manufacturing through the same period, a build-out a merger could complicate rather than accelerate.
The scale of the selloff suggests investors read the talks as dilutive rather than additive to AstraZeneca's standalone case. With Soriot's growth targets predicated on organic pipeline execution and a heavy US manufacturing commitment already underway, a merger of this size would inject integration risk and strategic uncertainty into a growth story that had been running largely on its own steam. Until either side confirms or denies the reports, the market looks set to treat AstraZeneca's valuation as hostage to deal speculation rather than fundamentals.
Edx Medical's pneumonia test goes live in NHS intensive care
Edx Medical Group (AIM:EDX) confirmed its rapid pneumonia test is now deployed in NHS clinical practice, having completed development and technical validation with partners. The Ventilator-Acquired Pneumonia test detects viral, fungal and bacterial pathogens from a lung fluid sample, guiding antibiotic prescribing for critically ill patients on the John Farman Intensive Care Unit at Addenbrooke's Hospital in Cambridge. Shares eased 2.4% to 10.25p despite the milestone.
Results reach authorised ICU staff via a secure digital link within hours, replacing traditional microbiological assays that can take several days. That speed matters at scale: hospital-acquired pneumonia costs the NHS an estimated £1.5 billion a year and consumes almost one million bed days, much of it considered avoidable through earlier detection. Cambridge University Hospitals NHS Foundation Trust and Edx Medical have signed a four-year service agreement covering the assay, building on Edx's 2025 licensing of the underlying intellectual property from the trust.
"We are now working to generate real world data for regulators in order to make the VAP test available more widely as soon as possible and to help improve antibiotic custodianship and control of MRSA," said Mike Hudson, chief executive of Edx Medical. The regulatory pathway now underway is the real test of commercial scale, live deployment at one flagship ICU proves clinical utility, but wider NHS and European rollout depends on the real-world data package Hudson describes generating next.
BSF Enterprise strikes US joint venture for T-Rex Leather
Bsf Enterprise (LSE:BSFA) has agreed non-binding Heads of Terms with US brand operator IMPOSTER to form a 50/50 joint venture commercialising its T-Rex Leather™ material across North America. The London-listed tissue engineering company will contribute technology licensing and material supply access rather than cash, with shares surging 41% to 1.2p on the news.
The venture, formed via BSF's subsidiary Lab-Grown Leather, targets small luxury goods including bag charms, keyrings, equestrian accessories and bespoke handbags and wallets, with showcase items due at the Hampton Classic Horse Show this month, New York Fashion Week in September and the Humane World Gala in November. BSF retains full ownership of its underlying patents and cellular technology, plus independent commercial rights across higher-volume categories such as footwear, apparel, automotive interiors and mass-market handbags; full category exclusivity for IMPOSTER only activates in phase two.
"Partnering with IMPOSTER gives us an immediate, funded platform to showcase T-Rex Leather™ directly to high-net-worth individuals and luxury buyers... without committing BSF cash capital," said Che Connon, chief executive of BSF Enterprise. Structuring the deal without cash outlay preserves BSF's balance sheet while buying real-world brand exposure in a market where lab-grown materials still need to prove consumer appetite.
Cizzle's US partner adds second lab for lung cancer test
Cizzle Biotechnology Holdings (LSE:CIZ) said its North American licensing partner has signed a laboratory agreement with BioBridge Global, a San Antonio-based healthcare services organisation specialising in laboratory medicine and biomanufacturing. Shares nudged up 0.95% to 2.019p as the diagnostics developer extended its US commercial footprint.
The CIZ1B Biomarker Blood Test for Lung Cancer will be offered by BBG Advanced Therapies, a BioBridge subsidiary, to licensed healthcare providers across South Texas once the lab completes its own validation. It marks the second clinical laboratory group to sign on since the test, a laboratory-developed test requiring independent validation at each site, gained CLIA certification and began initial sales at OmniHealth Diagnostics on 16 June.
"Early detection can dramatically improve outcomes, yet too many patients are diagnosed after lung cancer has progressed," said Bill Behnke, founder of BIO. Each new laboratory signing widens the addressable patient population without Cizzle itself bearing validation costs, a licensing model that lets the small-cap scale US distribution through partners' existing lab infrastructure rather than building its own.
New UK guideline backs Genedrive point-of-care test
A new UK clinical guideline recommends MT-RNR1 genotype testing before aminoglycoside treatment, explicitly naming genedrive (AIM:GDR)'s point-of-care kit for use in acute care settings. Shares rose 5% to 1.05p on the endorsement.
The guidance targets a genetic variant that can cause irreversible hearing loss in patients given aminoglycoside antibiotics, positioning genedrive's rapid test as a screening tool clinicians can act on before prescribing rather than after harm occurs. Formal guideline recognition typically underpins NHS procurement decisions, giving the company a clearer route to adoption across acute care settings nationally.
CelLBxHealth study backs Parsortix for ADC target detection
Independent researchers demonstrated that CelLBxHealth (AIM:CLBX)'s Parsortix platform can detect antibody-drug conjugate targets on circulating tumour cells that conventional capture methods missed. Shares gained 3.9% to 1.325p following the findings.
The result strengthens Parsortix's positioning in a fast-growing ADC drug class, where identifying the right tumour targets on circulating cells is increasingly central to matching patients with therapy. Third-party validation from researchers outside the company adds independent weight to CelLBxHealth's technology claims ahead of any commercial licensing discussions.
Coiled Therapeutics doses first patient with new AO-252 formulation
Coiled Therapeutics (AIM:COIL) dosed the first US patient with a reformulated version of its lead cancer drug, a step toward planned dose-expansion trials in ovarian and prostate cancer. Shares edged up 0.82% to 9.83p on the update.
The precision oncology company's move to a new formulation typically signals improved manufacturability or dosing characteristics ahead of larger trials, and clearing first-patient dosing de-risks the transition before Coiled commits to the broader expansion studies it has planned in the two indications.
Genflow advances SIRT6 patent portfolio in US and Europe
Genflow Biosciences (AIM:GENF) updated on progress across its two core SIRT6 patent families, including a new US publication and accelerated examination of its foundational compound patent. Shares jumped 16.4% to 1.95p on the news.
Securing broader and faster patent protection roughly its SIRT6 longevity platform underpins Genflow's ability to defend its intellectual property as it advances toward clinical development, an increasingly important asset base for a pre-revenue biotech whose valuation rests largely on the strength of its underlying science.
